SCHEMBL4049174

SCHEMBL4049174

OCc1cccnc1-c1ccc(Cl)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 2/20 0.47
IDO1 P14902 1/20 0.43
TDO2 P48775 1/20 0.43
NR4A2 P43354 1/20 0.43
KCNA5 P22460 4/20 0.43
KCNN4 O15554 2/20 0.43
CCR9 P51686 1/20 0.42
KDM4E B2RXH2 4/20 0.41
GAA P10253 3/20 0.41
RAB9A P51151 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
ALDH1A1 P00352 1/20 0.41
GLA P06280 1/20 0.41
NOTUM Q6P988 2/20 0.41
PDK1 Q15118 1/20 0.40
DPP4 P27487 1/20 0.40
LMNA P02545 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
NPC1 O15118 1/20 0.40
HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4592340 0.85 KDM4E (0.41) TRPV1IDO1TDO2KCNA5KCNN4
SCHEMBL2889939 0.82 TRPV1 (0.47) TRPV1KCNA5KCNN4KDM4EGAA
SCHEMBL30832971 0.82 KDM4E (0.48) TRPV1KCNA5KCNN4CCR9KDM4E
SCHEMBL7160604 0.82 KDM4E (0.48) TRPV1KCNA5KCNN4CCR9KDM4E
SCHEMBL3719145 0.81 TRPV1 (0.47) TRPV1KDM4EGAARAB9ASMN1; SMN2
SCHEMBL17455924 0.81 TRPV1 (0.46) TRPV1KCNA5KCNN4KDM4EGAA
SCHEMBL5093163 0.81 KCNA5 (0.60) IDO1TDO2KCNA5KCNN4CCR9
Hydrochloric Acid SCHEMBL9030551 0.80 TRPV1 (0.46) TRPV1KDM4EGAARAB9ASMN1; SMN2
SCHEMBL792165 0.80 CCR9 (0.45) TRPV1IDO1TDO2KCNA5KCNN4
SCHEMBL28279884 0.79 PTGS2 (0.51) TRPV1IDO1TDO2KDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0799159-A1 DECHLORINATION OF TCE WITH PALLADIZED IRON Research Corporation Technologies, Inc (US) 1997-10-08 EP claimed
US-5616253-A Dechlorination of TCE with palladized iron RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 1997-04-01 US claimed
WO-1996020137-A1 DECHLORINATION OF TCE WITH PALLADIZED IRON RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 1996-07-04 WO claimed
EP-3919056-B1 COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN GLOBAL BLOOD THERAPEUTICS INC (US) 2024-08-28 EP disclosed
US-20230322704-A1 COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN GLOBAL BLOOD THERAPEUTICS, INC. 2023-10-12 US disclosed
US-20230322704-A1 COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN GLOBAL BLOOD THERAPEUTICS, INC. 2023-10-12 US disclosed
US-20230322704-A1 COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN GLOBAL BLOOD THERAPEUTICS, INC. 2023-10-12 US disclosed
US-11530191-B2 Compounds and uses thereof for the modulation of hemoglobin GLOBAL BLOOD THERAPEUTICS, INC. (US) 2022-12-20 US disclosed
US-11530191-B2 Compounds and uses thereof for the modulation of hemoglobin GLOBAL BLOOD THERAPEUTICS, INC. (US) 2022-12-20 US disclosed
EP-3919056-A1 COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN Global Blood Therapeutics, Inc. (US) 2021-12-08 EP disclosed
US-20210352892-A1 MACROMOLECULAR AND NONPARTICULATE AGROCHEMICALS TO REDUCE VAPOR DRIFT UNIVERSITY OF UTAH RESEARCH FOUNDATION 2021-11-18 US disclosed
US-6319939-B1 P-(HETEROCYCLIC METHYL)-SUBSTUTED ANILIDES ARE POTENT INHIBITORS OF THE RETINOIC ACID METABOLISM JANSSEN PHARMACEUTICA N.V. (BE) 2001-11-20 US disclosed
CN-1057995-C Substituted ortho-ethenylphenylacetic acid derivatives BSAF AG (DE) 2000-11-01 CN disclosed
EP-1037880-A1 RETINOIC ACID MIMETIC ANILIDES JANSSEN PHARMACEUTICA N.V. (BE) 2000-09-27 EP disclosed
WO-1999029674-A1 RETINOIC ACID MIMETIC ANILIDES JANSSEN PHARMACEUTICA N.V. (BE) 1999-06-17 WO disclosed
EP-0824504-A1 IMPROVED DESTRUCTION OF ELECTRON AFFINIC CONTAMINANTS DURING WATER TREATMENT USING FREE RADICAL PROCESSES Research Corporation Technologies, Inc (US) 1998-02-25 EP disclosed
WO-1996035642-A1 IMPROVED DESTRUCTION OF ELECTRON AFFINIC CONTAMINANTS DURING WATER TREATMENT USING FREE RADICAL PROCESSES RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 1996-11-14 WO disclosed
US-4267280-A Controlled release pesticides and method of preparation HOPKINS, MADISON WISCONSIN A CORP OF WISCONSIN 1981-05-12 US disclosed
US-4225693-A CONTROLLED RELEASE HOPKINS AGRICULTURAL CHEMICAL COMPANY 1980-09-30 US disclosed
US-4116665-A Method of regulating the growth of aquatic weeds with pyridine derivatives ELI LILLY AND COMPANY (US) 1978-09-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230322704-A1 COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN HBG2, HBG1, HBB TRPV1 3983/4885IDO1 2927/4885TDO2 634/4885
US-20210352892-A1 MACROMOLECULAR AND NONPARTICULATE AGROCHEMICALS TO REDUCE VAPOR DRIFT ACP1, PTMS, VDAC1 TRPV1 1597/4885IDO1 2214/4885TDO2 906/4885
US-11530191-B2 Compounds and uses thereof for the modulation of hemoglobin HBG2, HBG1, HBB TRPV1 3983/4885IDO1 2927/4885TDO2 634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.